Compare Adaptive Biotechnologies Corp (ADPT) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Innovative Industrial Properties Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Innovative Industrial Properties Inc trades at $62.81 (market cap $1.79B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Innovative Industrial Properties Inc pays a 12.3% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | IIPR | |
|---|---|---|
Market Cap | $3.33B | $1.79B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $63.40 |
52-Week Low | $10.24 | $44.58 |
Enterprise Value | $3.19B | $2.18B |
Dividend Yield | — | 12.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
IIPR trades at $61.81, down 2.51% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported a Q1 2026 EPS beat of $1.88 versus $1.07 expected, though revenue has declined from $310M in 2023 to $266M in 2025. Recent news highlights progress on cannabis rescheduling as a potential tailwind and the declaration of a $1.90 dividend for Q2 2026.
The outlook is mixed; a high dividend yield and low P/E of 15.78 offer value, but declining revenue and negative net cash flow pose risks. Analyst sentiment is cautious with a majority Hold rating. Upside depends on stabilizing tenant operations and regulatory progress, while downside risks include further revenue pressure and sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
